Literature DB >> 14499242

Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival.

Katsuhiko Kaneko1, Adrian E Morelli, Zhiliang Wang, Angus W Thomson.   

Abstract

Ethylcarbodiimide (ECDI) couples soluble antigens (Ag) to lymphoid cells bestowing tolerizing potential. We examined whether ECDI-treated allogeneic dendritic cells (DC) could promote Ag-specific T cell unresponsiveness and prolong graft survival. Exposure of murine myeloid DC to ECDI did not affect surface immunophenotype but reduced their ability to cluster with T cells, enhanced their apoptotic death, and markedly reduced their allostimulatory activity. Anti-donor proliferative and cytotoxic T cell responses of mice primed with ECDI-treated DC were markedly inhibited. Secretion of both Th1 (IFNgamma) and Th2 cytokines (IL-5, IL-10) was suppressed. Cardiac allograft survival in mice preconditioned with a single injection of ECDI-DC was prolonged significantly. These results indicate that ECDI-treated DC promote T cell unresponsiveness to donor alloAgs and prolong transplant survival. The effects are not associated with sparing of Th2 responses, but may reflect inhibitory effects of apoptotic donor DC on host immune reactivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499242     DOI: 10.1016/s1521-6616(03)00141-4

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

Review 1.  Targeted immunomodulation using antigen-conjugated nanoparticles.

Authors:  Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-03-10

Review 2.  Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.

Authors:  Peter Y Li; Zhiyuan Fan; Hao Cheng
Journal:  Bioconjug Chem       Date:  2018-01-11       Impact factor: 4.774

Review 3.  Apoptotic cell-based therapies for promoting transplantation tolerance.

Authors:  Anil Dangi; Shuangjin Yu; Xunrong Luo
Journal:  Curr Opin Organ Transplant       Date:  2018-10       Impact factor: 2.640

Review 4.  Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells.

Authors:  D P McCarthy; J Bryant; J P Galvin; S D Miller; X Luo
Journal:  Am J Transplant       Date:  2015-03-23       Impact factor: 8.086

5.  Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation.

Authors:  Aaron J Martin; Derrick McCarthy; Carl Waltenbaugh; Gwen Goings; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2010-08-16       Impact factor: 5.422

6.  Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells.

Authors:  Michael H Albert; Xue-Zhong Yu; Thomas Magg
Journal:  Clin Immunol       Date:  2008-09-25       Impact factor: 3.969

7.  Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions.

Authors:  G Chen; T Kheradmand; J Bryant; S Wang; J Tasch; J-J Wang; Z Zhang; X Luo
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

8.  ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms.

Authors:  Xunrong Luo; Kathryn L Pothoven; Derrick McCarthy; Mathew DeGutes; Aaron Martin; Daniel R Getts; Guliang Xia; Jie He; Xiaomin Zhang; Dixon B Kaufman; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-16       Impact factor: 11.205

Review 9.  Exploiting apoptosis for therapeutic tolerance induction.

Authors:  Daniel R Getts; Derrick P McCarthy; Stephen D Miller
Journal:  J Immunol       Date:  2013-12-01       Impact factor: 5.422

Review 10.  Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation.

Authors:  Huize Yan; Dan Shao; Yeh-Hsing Lao; Mingqiang Li; Hanze Hu; Kam W Leong
Journal:  Adv Sci (Weinh)       Date:  2019-05-22       Impact factor: 16.806

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.